科普文章
xLinkMsAb,新一代T细胞接合剂(TCE)激动性抗体
图1.TCEs的市场预测[2]。全球bsAb肿瘤市场预计将迅速扩大,预计到2027年销售额将接近37亿美元(图1) [2]。
表1.已批准的和临床晚期TCE
ALL:急性B淋巴细胞白血病 NHL: 非霍奇金淋巴瘤 DLBCL:弥漫大B淋巴瘤 FL:滤泡性淋巴瘤 MM:多发性骨髓瘤 SCLC:小细胞肺癌
表2. 上市或临床后期开发阶段TCE的不良反应和有效性
ORR:客观缓解率 CR:完全缓解 VGPR:非常好的部分缓解 OS:总生存期
表3. TCE与CART的比较
图2:在接受CD19 4-1BBL联合glofitamab或单药治疗的人源化NOG小鼠中,WSU DLCL2模型中的肿瘤体积退缩。为了证明与CD19 4-1BBL的潜在协同作用,我们以次优剂量给予了Glofitamab。CD3的免疫组织化学(IHC)染色显示淋巴瘤组织中T细胞内流增加,这一情况在glofitamab联合治疗组中优于对照组(IHC图) [18]。
图3:xLinkMsAb:肿瘤抗原依赖的CD3/4-1BB共激活TCE
1. Wang, S., et al., The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med, 2021. 13(9): p. e14291.
2. Esfandiari, A., S. Cassidy, and R.M. Webster, Bispecific antibodies in oncology. Nat Rev Drug Discov, 2022. 21(6): p. 411-412.
3. Subklewe, M., BiTEs better than CAR T cells. Blood Adv, 2021. 5(2): p. 607-612.
4. Kantarjian, H., et al., Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med, 2017. 376(9): p. 836-847.
5. Nathan, P., et al., Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med, 2021. 385(13): p. 1196-1206.
6. Michael Dickinson, C.C.-S., Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Thomasz Wróbel, Fritz Offner, Marek Trněný, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings, GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS. EHA, 2022.
7. Budde, L.E., et al., Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet Oncology, 2022. 23(8): p. 1055-1065.
8. Catherine Thieblemont, T.P., Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Limei Poon, Thomas Doerr, Nurgul Kilavuz, Menghui Chen, Mariana Sacchi, Brian Elliott, Martin Hutchings, Pieternella Lugtenburg, PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY. EHA, 2022.
9. Jakubowiak, A.J., et al., Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. Journal of Clinical Oncology, 2022. 40(16_suppl): p. 8014-8014.
10. Moreau, P., et al., Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2022. 387(6): p. 495-505.
11. Bannerji, R., et al., Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. The Lancet Haematology, 2022. 9(5): p. e327-e339.
12. Minnema, M.C., et al., Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1. Journal of Clinical Oncology, 2022. 40(16_suppl): p. 8015-8015.
13. AMGEN, Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer. Press Releases, 2022.
14. Jeffrey A Zonder, J.R., Naresh Bumma, Jason Brayer, James E Hoffman, William I Bensinger, Ka Lung Wu, Linzhi Xu, Dhruti Chokshi, Anita Boyapati, Damien Cronier, Yariv Houvras, Karen Rodriguez Lorenc, Glenn S Kroog, Madhav V Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath, EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. EHA, 2022.
15. Kumar, S., et al., A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021. 138(Supplement 1): p. 900-900.
16. Chester, C., et al., Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018. 131(1): p. 49-57.
17. Hutchings, M., et al., Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood, 2020. 136: p. 46-48.
18. Hutchings, M., et al., Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. Blood, 2020. 136: p. 16-17.
19. Kegyes, D., et al., Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol, 2022. 15(1): p. 78.